Improving and assuring newborn screening laboratory quality worldwide: 30-year experience at the Centers for Disease Control and Prevention.
Newborn screening is the largest population-based genetic screening effort in the United States. The detection of treatable, inherited congenital disorders is a major public health responsibility. The Centers for Disease Control and Prevention's (CDC's) Newborn Screening Quality Assurance Program helps newborn screening laboratories ensure that testing accurately detects these disorders, does not delay diagnosis, minimizes false-positive reports, and sustains high-quality performance. For over 30 years, the CDC's Newborn Screening Quality Assurance Program has performed this essential public health service, ensuring the quality and accuracy of screening tests for more than 4 million infants born each year in the United States and millions more worldwide. The Program has grown from 1 disorder in 1978 for 31 participants to more than 50 disorders for 459 participants in 2009. This report reviews the Program's milestones and services to the newborn screening community.
De Jesús
Víctor R
VR
Newborn Screening Quality Assurance Program, Division of Laboratory Sciences, National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. vdejesus@cdc.gov
Mei
Joanne V
JV
Bell
Carol J
CJ
Hannon
W Harry
WH
D015415:Biomarkers / Q000097:blood; D002487:Centers for Disease Control and Prevention, U.S.; D014943:Global Health; D006801:Humans; D007231:Infant, Newborn; D007753:Laboratories / Q000592:standards*; D015997:Neonatal Screening / Q000331:legislation & jurisprudence / Q000592:standards*; D011785:Quality Assurance, Health Care / Q000592:standards*; D011786:Quality Control; D013048:Specimen Handling / Q000592:standards; D014481:United States
D015415:Biomarkers